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COMMENTARY
Paracrine effects of TLR4-polarised 
mesenchymal stromal cells are mediated 
by extracellular vesicles
Marie‑Theres Zeuner1, Ketan Patel2,3, Bernd Denecke4, Bernd Giebel5 and Darius Widera1* 
Abstract 
Mesenchymal stromal cells (MSCs) are adult stem cells able to give rise to bone, cartilage and fat cells. In addition, 
they possess immunomodulatory and immunosuppressive properties that are mainly mediated through secretion 
of extracellular vesicles (EVs). In a previous issue of Journal of Translational Medicine, Ti and colleagues demonstrated 
that preconditioning of MSCs with bacterial lipopolysaccharides results in secretion of EVs that can polarise mac‑
rophages towards anti‑inflammatory M2 phenotype. Moreover, the authors suggest that EVs of  lipopolysaccharide 
(LPS)‑treated MSCs are superior to EVs of untreated MSCs concerning their ability to support wound healing. Our 
commentary critically discusses parallel efforts of other laboratories to generate conditioned media from stem cells 
for therapeutic applications, and highlights impact and significance of the study of Ti et al. Finally, we summarise its 
limitations and spotlight areas that need to be addressed to better define the underlying molecular mechanisms.
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Multipotent MSCs can be easily raised from a variety of 
adult human tissues and organs, including bone marrow 
and adipose tissue [1], and possess immunomodulatory 
capabilities affecting the majority of immune cells [2]. As 
of Nov 2015, more than 540 clinical trials utilising MSCs 
have been registered in the database clinicaltrials.org [3].
It turns out that the therapeutic benefit of MSC-admin-
istration revealed in different proof of concept and clini-
cal studies (for review see [4]) is frequently connected to 
paracrine/endocrine effects rather than to effects driven 
by the engraftment of MSCs into affected tissues and dif-
ferentiation towards lost cell types [5–9].
Related to their proposed paracrine mode of action, 
several pre-clinical reports and a clinical treatment 
attempt of a Graft-versus-host disease (GvHD) patient 
provided evidence that MSCs exert their therapeu-
tic functions via extracellular vesicles (EVs), such as 
exosomes and microvesicles [10–14]. Indeed, direct com-
parisons in mouse models of acute kidney failure and 
ischemic stroke revealed that MSCs and MSC-EVs exert 
comparable therapeutic effects [11, 12].
By definition, exosomes are small EVs (~70–150  nm) 
of endosomal origin, while microvesicles (100–1000 nm) 
bud from the plasma membrane [15, 16]. With the 
current technologies, nano-sized microvesicles and 
exosomes can hardly be discriminated at the experi-
mental level. Consequently, the International Society 
of Extracellular Vesicles (ISEV) recommended to use, 
at least at the experimental level, the term EV rather 
than exosomes and microvesicles [17]. EVs are found in 
all body fluids and are secreted by almost all cell types, 
under physiological and pathological situations. Nota-
bly both, the content (a specific combination of different 
proteins, lipids, microRNAs as well as a small portion of 
mRNAs) and immunomodulatory features of EVs are cell 
type and context-dependent [15, 16, 18–20].
Toll-like receptors (TLRs) are transmembrane recep-
tors which play pivotal roles in the innate immune system 
by recognizing a wide spectrum of pathogen-associated 
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molecules or pathogen-associated molecular pat-
terns (PAMPs) as well as endogenous danger-/dam-
age-associated molecular patterns (DAMPs) [21]. The 
toll-like receptor 4 (TLR4) recognises bacterial lipopoly-
saccharides (LPS) that depending on their chemotype 
can induce pro-inflammatory or immunosuppressive 
effects [22]. Importantly, also DAMPs are able to act as 
both, pro-inflammatory and immunosuppressive stim-
uli (reviewed in [23]). The binding of a ligand to TLR4 
results in the activation of both, MyD88-dependent and 
independent signalling pathways. The MyD88-dependent 
signalling culminates in nuclear translocation of the pro-
inflammatory transcription factor NF-κB dimers (p50 
and p65) and increased expression and secretion of pro-
inflammatory cytokines (e.g., TNF-α), whereas an active 
MyD88-independent pathway results in activation of 
IRF3 and synthesis of the anti-viral and anti-inflamma-
tory interferon-β [24].
MSCs express functional TLR4 [25, 26] but the con-
sequences of its activation on proliferation, differentia-
tion and migration seem to be largely dependent on the 
chemotype, purity and concentration of the ligand in 
addition to the duration of the exposure (reviewed in 
[27]). Besides such direct effects, MSCs can be efficiently 
polarised into a pro-inflammatory and anti-inflamma-
tory phenotype by ligands of TLRs leading to respective 
changes in their immunomodulatory properties [28]. 
It has been recently reported that preconditioning of 
adipose-derived MSCs with low concentration of LPS 
(0.5 ng/ml, unspecified chemotype) improves the regen-
erative effects of MSCs-secretome in experimental hepa-
tectomy in mice [29].
Here, we comment on the original research article by 
Ti and colleagues published recently in Journal of Trans-
lational Medicine [30]. In their study, the authors pre-
conditioned umbilical cord-derived human MSCs with 
100 ng/mL LPS (chemotype and purity not specified) for 
48 h followed by collection of the supernatant and isola-
tion of EVs via ultracentrifugation. They provide evidence 
that EVs of preconditioned MSCs are able to induce 
polarisation of the THP-1 monocyte cell line towards 
the anti-inflammatory M2 phenotype demonstrated by 
significant reductions in the levels of pro-inflammatory 
cytokine mRNA (IL-6, IL-1 and TNF-α) and increased 
expression of anti-inflammatory transcripts IL-10 and 
TGF-β. Subsequently, Ti et al. were able to demonstrate 
that preconditioning of MSCs with LPS causes a change 
of EV miRNA cargo. They identified let-7b to be up-regu-
lated most prominently among all of the 40 differentially 
expressed miRNAs. This is highly relevant since tumour 
suppressor miRNA let-7b is known to participate in 
regulation of cell proliferation and apoptosis and targets 
TLR4 [31, 32]. Similarly, in the study by Ti and colleagues, 
let-7b over-expression resulted in a significant decrease 
of TLR4 protein in THP-1 cells. Finally, in a rat model 
of diabetes, the application of EVs of preconditioned 
MSCs into cutaneous wound led to reduced infiltration 
of inflammatory cells and greatly improved the overall 
wound healing. Notably, EVs released by non-LPS treated 
MCS seem to transmit some beneficial effects in terms of 
tissue regeneration, albeit less pronounced than effects 
mediated by EVs released by LPS-treated cells. However, 
a major shortcoming of the study is the lack of quantita-
tive data regarding the effects of EVs in the in vivo wound 
healing model hampering a direct comparison between 
the respective experimental groups. In general, diabetic 
wound healing models in rodents represent a potent tool 
in regenerative medicine and allow quantitative measure-
ment of regeneration by assessing the epithelial gap and 
wound contraction [33]. Such quantitative parameters 
would greatly facilitate the evaluation of the effects of 
MSC-derived EVs on wound healing.
In summary, Ti and colleagues show that LPS modu-
lates the secretome of umbilical MSCs. The authors 
demonstrate that EVs secreted by LPS-treated MSCs are 
anti-inflammatory and immunomodulatory. They further 
suggest that these effects are at least partly mediated by 
EV miRNA cargo. Finally, this study suggests that the EV 
fraction released from LPS-treated MSCs is enriched for 
the miRNA let-7b, which is known to target the TLR4/
NF-κB signalling pathway.
Although this study has high translational poten-
tial, there are several open questions that need to be 
addressed in future. Firstly, the study does not include 
LPS-treated MSCs as a control group in the wound heal-
ing model. Ideally, a direct comparison of the effects 
of transplanted EVs and the parental cells should be 
performed.
Secondly, the fate of LPS-treated MSCs remains an 
unresolved question. Since MSCs themselves can be 
polarised into pro- and anti-inflammatory phenotypes 
[28, 34], it is of major interest whether the pro- or anti-
inflammatory polarised MSCs secrete the anti-inflamma-
tory EVs. In the present study, the stimulation of MSCs 
with LPS has been performed in serum-free medium. 
Notably, fetal calf serum (FCS) contains soluble CD14. As 
human MSCs lack the expression of CD14 [35, 36] that 
is believed to be necessary for induction of the MyD88 
independent (anti-inflammatory) signalling pathway [37, 
38], it could be presumed that most of the cells in this 
study underwent pro-inflammatory polarisation.
To investigate the ability of MSC-EVs to polarise mac-
rophages, human monocytic cell line THP-1, origi-
nally isolated from peripheral blood of a 1-year-old 
male patient suffering from acute monocytic leukemia, 
has been applied [39]. Although widely used to study 
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monocyte/macrophage functions, THP-1-derived mac-
rophages differ from primary macrophages in terms of 
proliferation rate, expression pattern and notably also in 
terms of their sensitivity to LPS [40]. Thus, primary mac-
rophages (e.g., derived from PBMCs) would represent a 
more appropriate cell population to test the EV-mediated 
polarisation.
Another major question to address is the role that 
let-7b plays in the process of diabetic wound closure. It 
would be of interest to determine whether the introduc-
tion of let-7b alone to the wound bed would sufficient to 
promote tissue regeneration by modulating the polarisa-
tion of macrophages. This would be an attractive thera-
peutic avenue since miRNA can be delivered to the lesion 
site using relatively safe vectors including the AAV family.
Another unresolved issue is the impact of different 
TLR4 ligands on the EV polarisation. In this context, it 
is noteworthy that the balance between the NF-κB sig-
nalling and the IRF3 activity is largely ligand-dependent 
[41]. Unfortunately, the study by Ti et  al. does not pro-
vide information on the chemotype and purity of the LPS 
used, which both play a pivotal role in the downstream 
signalling (reviewed in [27]). In particular, standard 
LPS preparations activate TLR2 in addition to TLR4. In 
contrast to TLR4, TLR2 exclusively signals through the 
MyD88-dependent pathway and lacks the ability to acti-
vate IRF3. Thus, different LPS ligands induce fundamen-
tally different downstream signalling cascades and could 
trigger different autocrine effects in MSCs.
Finally, since EVs contain a context-dependent and cell 
type specific combination of different proteins and lipids 
in addition to miRNAs, a holistic comparison of the cargo 
between EVs of LPS-treated and control MSCs could lead 
to better understanding of their regenerative properties.
Conclusions
Beyond its immediate relevance for the biology of 
MSCs, the study by Ti et  al. establishes a perspective 
for improvement of cell-free therapy concepts in trans-
lational regenerative medicine. In future, EVs of in vitro 
“programmed” MSCs through inflammatory or damage 
signals could represent a promising and realistic alterna-
tive to stem cell transplantation. To exploit this poten-
tial, however, future research needs to unravel in detail 
their mode of action. Prior to therapeutic use it will be 
important to establish if pro- or anti-inflammatory polar-
ised MSCs secrete the beneficial EVs. In addition, it will 
be interesting to treat MSCs with defined ultrapure LPS 
of different chemo- and serotypes prior to EV isolation. 
Such polarisation of MSCs via appropriate inflammatory 
signals could allow generating EVs with either pro- or 
anti-inflammatory properties. Notably, regeneration of 
various tissue including skeletal muscles require both, 
pro-inflammatory signals that drive proliferation and 
migration of progenitors as well as anti-inflammatory sig-
nals that regulate their differentiation and survival [42].
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